Summanr Four of 12 Chinese patients receiving BACOP. in combination with recombinant human granulocyte colony-stimulating factor. for aggressive non-Hodgkin's lymphoma developed a rapidly progressive pneumonic illness characterised by diffuse pulmonary infiltrates and hypoxaemia. The condition proved fatal in three. and in none could an infective cause be identified. A retrospective analysis revealed only one episode of pneumonia in the previous 24 patients in whom the same BACOP regimen was administered without granulocvte colony-stimulating factor support. Granulocyte colony-stimulating factor, by augmenting white cell production. pulmonary sequestration and margination and production of toxic oxygen species. may exacerbate underlying subclinical bleomycin pulmonary toxicity. Caution should be exercised before using granulocyte-stimulating factors in bleomycin-containing regimens.
granulocyte-stimulating factors in bleomycin-containing regimens.
Myelosuppression is the major factor contributing to infection. mortality, morbidity and dose reduction in patients receiving cytotoxic chemotherapy (Pizzo. 1984 , Pizzo & Meyers, 1989 . Recombinant human granulocyte colonystimulating factor (G-CSF) has been demonstrated to stimulate the proliferation and differentiation of neutrophils and to be a clinically useful drug (Morstyn et al., 1988; Gabrilove et al., 1988a,b; Yoshida et al.. 1990 ). Accelerated recovery from neutropenia and reduction in associated neutropenic febrile and infective episodes have been documented (Morstyn et al., 1988; Sheridan et al., 1989; Bronchud et al., 1987 Bronchud et al., , 1988 Pettengell et al., 1992) . G-CSF has been well tolerated in most clinical trials and has not, until recently, been associated with serious adverse effects (Neidhart et al., 1989; Lindeman et al.. 1989) .
Recently, however, there have been three bnref reports suggesting that G-CSF may augment cytotoxic drug-induced pulmonary toxicity (Boogaerts et al., 1993; Iki et al., 1993; Matthews, 1993) . This has prompted us to describe our own experience in Chinese patients receiving the BACOP regimen for aggressive non-Hodgkin's lymphoma, during which we also encountered an unexpectedly high incidence of serious pulmonary complications. In order to assess the possible role of G-CSF more accurately, we compared the current series with the 24 of our previous patients receiving the same regimen without G-CSF support. Table I , the median number of courses of BACOP received by each patient was 4.5 (range 1-6) in the G-CSF group and 5 (range 3-6) in the control group. However, the total dose of bleomycin received by each patient was significantly lower in the G-CSF group (median 54.5 mg, range 28-108 mg) than in the control group (median 85 mg, range 40-108 mg). Of the 12 patients in the G-CSF group, seven (58%) achieved complete remission and two (17%) died early in the induction chemotherapy before scheduled assessment. Of the 24 patients in the control group, 17 (71%) achieved complete remission and one (4%) died before reassessment. Incidence of complications during induction chemotherapy The incidence of fever, leucopenia, pneumonia, respiratory failure and death from pneumonia and median nadir white cell count during the first and second courses of treatment (nadir I and nadir II) are shown in Table II . The number of febnrle episodes in the G-CSF group was 11 (92%), which was significantly higher than the control group 14 (58%). Leucopenic episodes in the G-CSF and control groups occurred in 9 and 22 patients respectively. There was no significant difference in the incidence of leucopenia between the G-CSF and the control groups. The median white cell nadir I and nadir II were 4.3 x 1091-l (range 0.5-9.5 x 109) and 2.8 x 1091-' (range 0.6-12.2 x 1091-') respectively in the G-CSF group compared with 1.5 x 1091-l (range 0.6-5 x 10091-') and 2 x 1091-l (range 0.8-8.4 x 1091-1) in the control group. The incidence of pneumonia, respiratory failure and death from pneumonia [4(33%), 3(25%) and 3 (25%) respectively] in the G-CSF group was significantly higher than in the control group, in which there was only a single case of pneumonia (4%) and no episodes of respiratory failure or related deaths were recorded (Table II) .
Case report of the three fatal cases Patient 1 was a 41-year-old man who received BACOP and G-CSF for stage IIA aggressive Non-Hodgkin's lymphoma diagnosed in November 1991. He achieved complete remission after two courses of treatment. After completing his third course of treatment, he developed fever, chills, a productive cough and dyspnoea. On examination, he had central cyanosis with marked tachypnoea and diffuse crepitations in his chest. The white cell count was 6.9 x 109 1-1, and arterial blood gases showed respiratory failure with Pao2 = 6.0 kPa (on 50% inspired oxygen). The chest radiograph revealed diffuse opacities with pneumonic changes and a ground-glass appearance in both lung fields (Figure 1 ). Broad-spectrum antibiotics were started but his condition progressed. posed on fifth and eighth ribs in left lung field). examination was normal. All cultures and bronchoavelolar lavage were negative. She did not respond to antibiotics and cotrimoxazole and died of severe pneumonia 7 days after admission.
Discas
In the first report of the use of BACOP in patients with non-Hodgkin's lymphoma. Skarin et al. (1977) described the development of pulmonary infiltrates in 21 73 (29%) of their patients, and three patients died from pulmonary insufficiency. More recently 23% of patients receiving m-BACOD in a large controlled clinical trial comparing this regimen with CHOP were also reported to have developed mild, severe or life-threatening pulmonary toxicity, characterised by pulmonary infiltrates and hypoxaemia (Shapiro et al., 1991) . The cause of this syndrome remains unknown. In the studies mentioned above no infective agent could be identified despite intensive investigation including transbronchial and open biopsy. and indeed this was our expenrence. Gordon et al.
(1992) suggested that either methotrexate or bleomycin might be involved, although the latter seemed to be implicated less frequently (Bauer et al., 1983) . Methotrexate was not a component of the original BACOP regimen which, as already noted, was associated with a high rate of pulmonary complications, and it has been suggested that the pulmonary toxicity of bleomycin is enhanced by combination with other drugs (Bauer et al., 1983; Shapiro et al., 1991) . The risk of bleomycin-induced pulmonary toxicity increases significantly at a cumulative dose greater than 500 units (Ginsberg et al., 1982) . (Skarin et al., 1977) . The total cumulative dose of bleomycin in our G-CSF group (median 54.5 mg) was well below the reported toxic level, and also significantly lower than in the historical control (median 85 mg).
The pulmonary toxicity of bleomycin has been attributed to production of reactive oxygen species which damage the pulmonary epithelium and stimulate influx of peripheral polymorphonuclear cells (Kreisman & Wolkove, 1992) . It is possible that recombinant G-CSF exacerbates this phenomenon by virtue of its actions of increasing the number of neutrophils and enhancing superoxide (0,-) release from neutrophils in response to stimuli (Ohsaka et al., 1989; Tanimura et al.. 1992) . It also rapidly increases the expression of adhesion-related molecule C3bi receptors on neutrophils. which together with increased neutrophil count may predispose to neutrophil aggregation in blood vessels (Ohsaka et al.. 1989) . Furthermore, G-CSF has been shown to induce a transient neutropenia, which may be related to tissue migration and,or increased adherence of neutrophils to endothelium (Bronchud et al.. 1988; Morstyn et al., 1989) . Consistent with this suggestion. Matthews (1993) (Iki et al., 1993) . The possibility of an ethnic difference in susceptibility to G-CSF must also be considered. However, other Chinese patients with nonHodgkin's lymphoma treated with G-CSF and CHOP have not experienced any unexpected pulmonary complications (R. Liang, personal communication).
We cannot exclude the possibility that unidentified pathogens may have been involved. The clinical course was so rapid as to exclude open lung biopsy and pulmonary function studies in most cases, and autopsy is seldom agreed to in our population. Similarly. clustering of patients with the well-recognised pulmonary complication of BACOP may have been coincidental in the G-CSF group. However, we believe our data are sufficiently striking to counsel caution before using G-CSF in combination with bleomycin. The move away from BACOP in favour of older regimens such as CHOP may render this problem less likely in the future.
